Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Stomach Neoplasms 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Multiple Myeloma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Capecitabine 35Oxaliplatin 32Fluorouracil 29Leucovorin 26Irinotecan 22Bevacizumab 19Cetuximab 17Radiotherapy 16Radiation 11Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Celecoxib 5Neoadjuvant Therapy 4Immunohistochemistry 4Biopsy 4Amplified Fragment Length Polymorphism Analysis 4cediranib 3Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Folfox protocol 3Drug Therapy 3Cisplatin 3sargramostim 2regorafenib 2pembrolizumab 2fludarabine phosphate 2aldesleukin 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rectal Neoplasms × dostarlimab × Clear all
NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

University of Iowa

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡